Transcript
Creatine monohydrate has been studied continuously for roughly 25 years. That longevity alone makes it unusual in the supplement world. What makes it genuinely remarkable is that the research has held up — and has expanded into areas most people haven't heard about yet. This episode works through what the evidence actually shows: for physical performance, for the brain, for women, for older adults, and for the persistent myths that follow the compound everywhere it goes.
Start with the basic biochemistry, because it matters for understanding everything that comes after.
Muscles run on ATP — adenosine triphosphate. During intense physical effort, cells burn through ATP faster than the aerobic system can regenerate it. The creatine kinase reaction bridges that gap. During brief maximal exercise, research from the Gatorade Sports Science Institute indicates that up to 80% of ATP is being regenerated via this reaction. Creatine, stored mainly as phosphocreatine in skeletal muscle, donates a phosphate group to spent ADP to rapidly rebuild ATP. It's a short-duration system — it doesn't sustain performance through a marathon — but for anything explosive, repeated, or intensely anaerobic, this system is central.
About 95% of the body's creatine sits in skeletal muscle. Smaller but meaningful amounts are present in the brain and heart. The body synthesises roughly half of what it needs from amino acids, primarily in the liver and kidneys. The rest typically comes from diet. Red meat and fish contain creatine — roughly 3 to 5 grams per kilogram of raw meat, or about 0.7 grams in a typical 6-ounce serving according to the GSSI. That dietary contribution is modest, and cooking degrades it further. For most people, there is meaningful room between baseline creatine stores and the physiological ceiling.
Supplementation fills that gap.
A 2024 systematic review and meta-analysis published in the journal Nutrients — looking specifically at adults under 50 combining creatine supplementation with resistance training — found a weighted mean difference in upper-body strength of 4.43 kilograms compared to placebo, with a p-value below 0.001. That's not a marginal finding. The effect was consistent across studies. Lower-body strength improvements followed a similar pattern, though with somewhat more variability between trials.
The GSSI's synthesis of 25 years of research is precise about where the performance benefit applies: brief, high-intensity exercise under 30 seconds, and especially repeated bouts of it. Sprint intervals, resistance training sets, high-intensity cycling, competitive team sports with repeated explosive efforts. The mechanism follows directly from the phosphocreatine system. More stored phosphocreatine means more capacity to buffer the ATP deficit during those critical early seconds.
One thing the evidence does not support is that more creatine produces proportionally more benefit. Muscle creatine stores have a saturation ceiling. When that ceiling is reached, additional supplementation is excreted. A common belief in gym culture is that higher doses produce greater gains. They don't. Excess creatine above saturation provides no ergogenic effect.
The loading debate is where marketing got ahead of the science.
The traditional loading protocol — 20 grams per day for five to seven days, typically divided into four doses — does work. It rapidly saturates muscle creatine stores. The GSSI confirms this. But speed is the only advantage loading offers. Taking 3 to 5 grams per day for approximately 28 days reaches the same saturation level and the same performance benefits. A study published in the Asian Journal of Sports Medicine via Brieflands, using a dose of 7.7 grams per day for 21 days, found significant improvements in strength, power output, and fatigue resistance in trained male athletes — without any loading phase at all.
The tradeoff is time. Loading achieves saturation in roughly a week; the lower daily dose produces the same outcome by the end of a month. For those who experience gastrointestinal discomfort on the higher divided doses of a loading phase, the slow-dose approach is a straightforward alternative. The GSSI does note that fewer studies have directly confirmed equivalent outcomes across all populations with the slow-dose protocol specifically — the principle is well-supported, but the granular population-level data is less complete.
One genuine side effect of the loading phase: body weight increases by approximately 0.5 to 1.0 kilograms. This is water retention, not fat. Creatine pulls water into muscle cells. It's transient and largely meaningless from a health perspective, but it's real and predictable.
The more recent area of creatine research concerns the brain.
Brain tissue also relies on rapid ATP regeneration, and creatine stores exist in neural tissue as well as muscle. Research reviewed in a ScienceDaily analysis of emerging creatine science found that supplementing with creatine raises creatine levels in the brain, and that this is associated with improvements in memory, processing speed, and mood. The effects are not uniform across all people — this is a crucial qualifier. The individuals who benefit most are those with lower baseline creatine levels: older adults, people who eat little or no meat, and people who are sleep-deprived or under significant physical or mental stress.
That specificity matters. For a well-rested young adult who eats meat regularly, the cognitive benefits of creatine supplementation are likely modest to negligible. The brain, like muscle, has a saturation ceiling. If someone is already close to it through diet and endogenous synthesis, supplementation doesn't push far above it.
For vegetarians and vegans, baseline creatine — including in the brain — is meaningfully lower. Studies in these populations have shown the strongest and most consistent cognitive responses to supplementation. Older adults represent a similar pattern: aging appears associated with lower muscle creatine stores, though whether this reflects a biological decline in synthesis or simply the reduced physical activity that typically accompanies aging is not yet settled.
The ScienceDaily review is explicit that more robust clinical trials are needed before creatine can be recommended for cognitive applications with clinical confidence. The mechanistic plausibility is solid and the early trial data is promising, but rigorous, large-scale, randomised controlled trials specifically targeting cognitive outcomes are still relatively sparse. The optimism in this area is earned but not yet fully proven.
Women deserve specific attention because most creatine research has been conducted in young men. The evidence base for women is thinner, and that thinness is itself a finding worth discussing.
Women typically have lower baseline creatine stores than men. By the same logic that applies to vegetarians, this implies more room to benefit from supplementation — a greater relative increase from a given dose. Whether this translates to proportionally larger performance improvements, similar improvements, or something different due to hormonal interactions is genuinely unclear.
The menstrual cycle almost certainly affects how creatine is processed and possibly how effective supplementation is at different phases, but this hasn't been studied with enough rigour to draw firm conclusions. Progesterone plays a role in creatine metabolism, but whether cycling creatine intake around menstrual phases makes practical sense is speculation at this point, not evidence-based guidance.
Older women face a compound challenge: age-related muscle loss, declining bone density, and the hormonal shifts of perimenopause and menopause. Early evidence suggests creatine may support muscle preservation and bone health in this demographic, making it potentially more valuable as a complement to resistance training than as a purely athletic supplement. But the specific trial data in this population is limited. The prior probability of benefit is reasonable; confirmation at clinical scale hasn't arrived yet.
On safety: after 25 years of clinical research in healthy adults, no confirmed adverse effects have emerged from creatine supplementation at recommended doses. The GSSI is unambiguous on this point. The kidney-damage concern traces back to a small number of case reports, and when those cases are examined carefully, they involve individuals with pre-existing kidney disease, polypharmacy, or other significant confounds. Creatine does raise creatinine levels in blood tests — creatinine is a breakdown product of creatine — and this can appear to indicate declining kidney function if a clinician doesn't know the patient is supplementing. Elevated creatinine in a creatine user is not kidney damage. It's a metabolic artifact of supplementation.
The absence of harm in healthy adults is not a subtle finding buried in small studies. It's a consistent result across decades of research in diverse populations. For someone with pre-existing kidney disease or a family history of renal problems, a conversation with a physician before supplementing is appropriate — the safety evidence applies specifically to healthy adults, and extrapolation to compromised kidney function cannot be assumed.
One more misconception worth addressing directly: creatine is not a steroid and is not analogous to one. The conflation appears often enough in public discourse to warrant being explicit. Creatine does not manipulate hormone levels and does not operate through androgenic pathways. It is a naturally occurring compound synthesised in the liver and kidneys, found in food, and stored in muscle. The mechanism — phosphocreatine donating a phosphate group to regenerate ATP — has no relationship to steroid biochemistry.
So: the central question is whether creatine is the one supplement where evidence and hype actually match, and whether that extends beyond muscle to brain and broader health.
For physical performance in high-intensity, short-duration exercise, the evidence is among the strongest accumulated for any supplement. The effect size is real, the mechanism is clear, and the research has replicated across decades and populations. The 4.43-kilogram upper-body strength advantage in the Nutrients meta-analysis represents a meaningful real-world difference for people combining creatine with resistance training.
For cognition, the evidence is promising and mechanistically credible, but not yet at the level where strong clinical claims are warranted. The people most likely to benefit — those with low baseline creatine due to diet, age, or elevated stress — are exactly the populations that traditional research has studied least.
For women and older adults, the plausibility of benefit is genuinely high, but the population-specific data is thin. The under-representation of women in creatine research is a real gap that limits what can be said with confidence about dosing, timing, and the influence of hormonal cycles.
On safety, the evidence is unusually reassuring. Twenty-five years of research in healthy adults without confirmed adverse effects places creatine in a category occupied by very few popular supplements.
What remains genuinely open: whether the slow-loading protocol performs identically to the fast-loading protocol across all populations and training contexts; whether creatine meaningfully affects concussion recovery, as some preliminary data hint; how much of the cognitive benefit in older adults reflects direct brain effects versus downstream improvements from better physical conditioning and sleep; and whether aging itself depletes muscle creatine through some biological mechanism distinct from reduced activity, or whether the activity decline explains it entirely. These questions represent the frontier of where creatine research is actually going, and the answers will likely refine, rather than overturn, what's already established.